^
Association details:
Biomarker:RET mutation
Cancer:Thyroid Gland Medullary Carcinoma
Drug Class:RET inhibitor
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

572P - Potential impact of molecularly-selected treatment in patients with endocrine neoplasms at a tertiary university hospital

Published date:
09/13/2021
Excerpt:
Two pts with BRAF mutated ATC received treatment with dabrafenib + trametinib, reaching an ORR of 100% and median PFS of 10 months. Five pts with RET mutated medullary thyroid cancer were treated with a selective RET inhibitor, achieving an ORR of 80%....Targeted therapy resulted in outstanding response rates and may have a significant survival benefit in aggressive tumors, such as ATC.